Toansa (Punjab), July 22 (Inditop.com) DSM Anti-Infectives, a subsidiary of Dutch pharmaceutical major Royal DSM NV, Wednesday opened its new plant here for producing Ampicillin, a widely used drug for bacterial infections.
“We are quite upbeat about the Indian market. This product (Ampicillin) will be used not only for the Indian Market but also for exports to the Middle East, Asia pacific and Africa,” Stefan Doboczky, president of DSM Anti-Infectives, told reporters in this Punjab town.
“We have a long-term commitment to the emerging global market and India in particular. We have invested multi-million dollars in this plant and will pump in more money to expand it when required.”
Doboczky, however, refused to divulge the investment details.
This new plant is part of the company’s plans to build a sustainable manufacturing base in India, he said, adding that the company has already made substantial investments in India to produce generic active pharmaceutical ingredients (API).
“What is more important is that this whole production is based on a green concept. We are using enzyme-base process which do not use any organic solvent. So the product is more safe, tastes better and has no side effects,” said Bharath Sesha, vice-president of DSM Anti-Infectives Asia (Middle East and Africa region).
“Also in this plant we will cut back on our energy and water consumption by almost half” to reduce the carbon emission, he added.
DSM Anti-Infectives is the world’s leading supplier of active pharmaceutical ingredients such as Amoxicillin, Ampicillin, Cephalexin and Cefadroxil.
The plant will employ about 450 direct workers and about 150 contractual workers.
rounak